CST castile resources ltd

This is from the original Prospectus."Technology...

  1. 2,515 Posts.
    lightbulb Created with Sketch. 214
    This is from the original Prospectus.

    "Technology Licence
    Cellestis holds the exclusive licence for Quantiferon
    technology from CSL Limited. This licence includes
    Quantiferon manufacturing and testing technology, all
    development data from clinical trials, and all associated
    information and intellectual property. The Quantiferon patents were registered in the name of CSIRO, and have been exclusively sub-licensed to Cellestis by agreement with CSL Limited and CSIRO."

    Just a question:

    Is there any caveat in the original licence agreements that prevents the Cellestis Board from selling this great bit of Australian biotechnology offshore without CSL and CSIRO approval?

    I would be happier to have CSL act as a "white knight" with a competitive offer to take us back and keep the product Australian owned....Brian McNamee are you interested? Happy to consider an offer of CSL shares for my CST holding.

    Also what would the attitude of the Foreign Review Board be to this proposed aquisition? Surely it cannot just let Cellestis go to an foreign company that essentially has little synergy to benefit what Cellestis already achieved. Taxpayer funds contributed to the original discoveries via the CSIRO and probably R & D grants and Tax concesions.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
5.6¢
Change
0.002(3.70%)
Mkt cap ! $17.12M
Open High Low Value Volume
5.4¢ 5.7¢ 5.4¢ $5.316K 95.38K

Buyers (Bids)

No. Vol. Price($)
1 100000 5.5¢
 

Sellers (Offers)

Price($) Vol. No.
5.7¢ 5789 1
View Market Depth
Last trade - 15.59pm 18/06/2025 (20 minute delay) ?
CST (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.